Insmed’s hypertension readout spurs $750M follow-on: Public Equity Report

A hypertension readout that propelled a lift in Insmed’s share price helped the company raise $750 million in the year’s largest follow-on by a NASDAQ-listed biotech.

Shares of Insmed Inc. (NASDAQ:INSM) rose 29% on Tuesday after the company said treprostinil palmitil (INS1009) led to a 35% placebo-adjusted reduction in pulmonary vascular resistance (p<0.001), meeting the primary endpoint in a Phase IIb trial to treat pulmonary arterial hypertension...